
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KBP-336
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
Details : KBP-336 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 19, 2025
Lead Product(s) : KBP-336
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : LY3541105
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : $1,400.0 million
Deal Type : Expanded Collaboration
KeyBioscience Announces Extension of Strategic Collaboration with Lilly
Details : Lilly will receive worldwide rights to develop and commercialize Dual Amylin Calcitonin Receptor Agonists (DACRA), a new class of potential treatments for obesity and related disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 10, 2024
Lead Product(s) : LY3541105
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : $1,400.0 million
Deal Type : Expanded Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KBP
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Eli Lilly | Nordic Bioscience | Profil Institut für Stoffwechselforschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KBP is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 08, 2019
Lead Product(s) : KBP
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Eli Lilly | Nordic Bioscience | Profil Institut für Stoffwechselforschung GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KBP-042
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Nordic Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
Details : KBP-042 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 26, 2017
Lead Product(s) : KBP-042
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Nordic Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
